Plasma fractionation issues

Albert Farrugia; Theo Evers; Pierre Francois Falcou; Thierry Burnouf; Luiz Amorim; Sylvia Thomas

doi:10.1016/j.biologicals.2009.01.005

Plasma fractionation issues

Albert Farrugia, Theo Evers, Pierre Francois Falcou, Thierry Burnouf, Luiz Amorim, Sylvia Thomas

Research output: Contribution to journal › Article › peer-review

34 Citations (Scopus)

Abstract

Procurement and processing of human plasma for fractionation of therapeutic proteins or biological medicines used in clinical practice is a multi-billion dollar international trade. Together the private sector and public sector (non-profit) provide large amounts of safe and effective therapeutic plasma proteins needed worldwide. The principal therapeutic proteins produced by the dichotomous industry include gamma globulins or immunoglobulins (including pathogen-specific hyperimmune globulins, such as hepatitis B immune globulins) albumin, factor VIII and Factor IX concentrates. Viral inactivation, principally by solvent detergent and other processes, has proven highly effective in preventing transmission of enveloped viruses, viz. HBV, HIV, and HCV.

Original language	English
Pages (from-to)	88-93
Number of pages	6
Journal	Biologicals
Volume	37
Issue number	2
DOIs	https://doi.org/10.1016/j.biologicals.2009.01.005
Publication status	Published - Apr 2009
Externally published	Yes

Keywords

Factor VIII
IVIG
Procurement of plasma
Protein fractionation
Viral inactivation

ASJC Scopus subject areas

Biotechnology
Applied Microbiology and Biotechnology
Bioengineering
Immunology and Microbiology(all)
Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.biologicals.2009.01.005

Cite this

@article{63ac664112224f5ebe6ee9d32728fbd2,

title = "Plasma fractionation issues",

abstract = "Procurement and processing of human plasma for fractionation of therapeutic proteins or biological medicines used in clinical practice is a multi-billion dollar international trade. Together the private sector and public sector (non-profit) provide large amounts of safe and effective therapeutic plasma proteins needed worldwide. The principal therapeutic proteins produced by the dichotomous industry include gamma globulins or immunoglobulins (including pathogen-specific hyperimmune globulins, such as hepatitis B immune globulins) albumin, factor VIII and Factor IX concentrates. Viral inactivation, principally by solvent detergent and other processes, has proven highly effective in preventing transmission of enveloped viruses, viz. HBV, HIV, and HCV.",

keywords = "Factor VIII, IVIG, Procurement of plasma, Protein fractionation, Viral inactivation",

author = "Albert Farrugia and Theo Evers and Falcou, {Pierre Francois} and Thierry Burnouf and Luiz Amorim and Sylvia Thomas",

year = "2009",

month = apr,

doi = "10.1016/j.biologicals.2009.01.005",

language = "English",

volume = "37",

pages = "88--93",

journal = "Journal of Biological Standardization",

issn = "1045-1056",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Plasma fractionation issues

AU - Farrugia, Albert

AU - Evers, Theo

AU - Falcou, Pierre Francois

AU - Burnouf, Thierry

AU - Amorim, Luiz

AU - Thomas, Sylvia

PY - 2009/4

Y1 - 2009/4

N2 - Procurement and processing of human plasma for fractionation of therapeutic proteins or biological medicines used in clinical practice is a multi-billion dollar international trade. Together the private sector and public sector (non-profit) provide large amounts of safe and effective therapeutic plasma proteins needed worldwide. The principal therapeutic proteins produced by the dichotomous industry include gamma globulins or immunoglobulins (including pathogen-specific hyperimmune globulins, such as hepatitis B immune globulins) albumin, factor VIII and Factor IX concentrates. Viral inactivation, principally by solvent detergent and other processes, has proven highly effective in preventing transmission of enveloped viruses, viz. HBV, HIV, and HCV.

AB - Procurement and processing of human plasma for fractionation of therapeutic proteins or biological medicines used in clinical practice is a multi-billion dollar international trade. Together the private sector and public sector (non-profit) provide large amounts of safe and effective therapeutic plasma proteins needed worldwide. The principal therapeutic proteins produced by the dichotomous industry include gamma globulins or immunoglobulins (including pathogen-specific hyperimmune globulins, such as hepatitis B immune globulins) albumin, factor VIII and Factor IX concentrates. Viral inactivation, principally by solvent detergent and other processes, has proven highly effective in preventing transmission of enveloped viruses, viz. HBV, HIV, and HCV.

KW - Factor VIII

KW - IVIG

KW - Procurement of plasma

KW - Protein fractionation

KW - Viral inactivation

UR - http://www.scopus.com/inward/record.url?scp=63249113806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63249113806&partnerID=8YFLogxK

U2 - 10.1016/j.biologicals.2009.01.005

DO - 10.1016/j.biologicals.2009.01.005

M3 - Article

C2 - 19289290

AN - SCOPUS:63249113806

SN - 1045-1056

VL - 37

SP - 88

EP - 93

JO - Journal of Biological Standardization

JF - Journal of Biological Standardization

IS - 2

ER -

Plasma fractionation issues

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this